With continuous improvement in cancer detection and treatment-induced tumor control, the number of cancer cures is increasing rapidly. However, cancer patients and survivors suffer from side effects, both during and after the completion of cancer therapy.
The research projects in the Center for Studies of Host Response to Cancer Therapy are designed to examine the mechanisms by which various types of cancer therapy cause toxicity and to develop strategies to prevent or reverse these side effects.
2024: Hunter Holthoff, M.D., Ph.D.
Insulin-like growth factor binding proteins in cisplatin-induced acute kidney injury
2023: KyoungHyun Kim, Ph.D.
Histone methylation in fatty liver disease-associated hepatocellular carcinoma
2023: Shelbie Stahr, Ph.D.
Heavy metal traces in saliva as markers of environmental exposure in breast cancer
2022: Michael Robeson, Ph.D.
Determining the role of probiotics in cognitive decline due to chemotherapeutics
2021: Samir Jenkins, Ph.D.
Photosensitizer-gold conjugates for X-ray induced photodynamic therapy of tumors
2021: Rajshekhar Kore, Ph.D.
MSC exosome mediated notch-1 signaling in radiation induced cardiac fibrosis repair
2019: Analiz Rodriguez, M.D., Ph.D.
Photobiomodulation of neuronal mitochondria treats radiation-induced cognitive dysfunction
2019: Amanda Stolarz, Pharm.D., Ph.D.
Mechanism by which doxorubicin contributes to lymphedema
2017: Brendan Frett, Ph.D.
Mitigating side effects of cancer therapy through Syk inhibition
2016: Antiño Allen, Ph.D.
Effects of methotrexate and cytosine arabinoside on cognition
2016: Nithin Karakala, M.D.
Identification of novel biomarkers in cisplatin induced acute kidney injury
2015: Allison Harrill, Ph.D.
miRNA biomarkers of cisplatin nephrotoxicity in genetically sensitive subjects
2015: Sharda Singh, Ph.D.
Attenuating doxorubicin cardiotoxicity with sulforaphane in patients with breast cancer